Electronic Supplementary material for the manuscript titled:

Efficacy and Safety of a Fixed-Dose Clindamycin 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug

Linda Stein Gold, MD[1]; Hilary Baldwin, MD[2,3]; Leon H Kircik, MD[4-6]; Jonathan S Weiss, MD[7,8]; David M Pariser, MD[9,10]; Valerie Callender, MD[11,12]; Edward Lain, MD, MBA[13]; Michael Gold, MD[14]; Kenneth Beer, MD[15]; Zoe Draelos, MD[16]; Neil Sadick, MD[17,18]; Radhakrishnan Pillai, PhD[19]; Varsha Bhatt, PhD[19]; Emil A Tanghetti, MD[20]

[1]Henry Ford Hospital, Detroit, MI
[2]The Acne Treatment and Research Center, Brooklyn, NY
[3]Robert Wood Johnson University Hospital, New Brunswick, NJ
[4]Indiana University School of Medicine, Indianapolis, IN
[5]Physicians Skin Care, PLLC, Louisville, KY
[6]Icahn School of Medicine at Mount Sinai, New York, NY
[7]Georgia Dermatology Partners, Snellville, GA
[8]Gwinnett Clinical Research Center, Inc., Snellville, GA
[9]Eastern Virginia Medical School Norfolk, VA
[10]Virginia Clinical Research, Inc., Norfolk, VA
[11]Callender Dermatology and Cosmetic Center, Glenn Dale, MD
[12]Howard University College of Medicine, Washington DC
[13]Austin Institute for Clinical Research, Austin, TX
[14]Tennessee Clinical Research Center, Nashville, TN
[15]University of Miami Miller School of Medicine, Miami, FL
[16]Dermatology Consulting Services, PLLC, High Point, NC
[17]Weill Cornell Medical College, New York, NY
[18]Sadick Dermatology, New York, NY
[19]Bausch Health US, LLC, Petaluma, CA
[20]Center for Dermatology and Laser Surgery, Sacramento, CA

Corresponding Author: Linda Stein Gold, MD
Affiliation: Henry Ford Hospital, Detroit, MI. Address: 6530 Farmington Rd, Ste 101 West Bloomfield, MI 48322. Telephone: (248) 661-8764. Email: LSTEIN1@hfhs.org

eFigure 1.Treatment success by visit (≥2-grade reduction from baseline in EGSS and a score of 0 [clear] or 1 [almost clear]) (ITT population).

Multiple imputation was used to impute missing values. *P<0.05, **P<0.01, ***P≤0.001 vs IDP-126. Data not shown: all active dyad treatments were significant versus vehicle at weeks 8 and 12 (P≤0.001, all); additionally, BPO/ADAP was significant versus vehicle at week 4 and CLIN/ADAP was significant versus vehicle at week 2 (P<0.05, both).

ADAP adapalene 0.15%, *BPO* benzoyl peroxide 3.1%, *CLIN* clindamycin phosphate 1.2%, *EGSS* Evaluator's Global Severity Score, *IDP-126* clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%, *ITT* intent to treat.



eFigure 2. Summary of cutaneous safety and tolerability evaluations.

No imputation of missing values (N values shown for baseline only). Data not shown for hyperpigmentation and hypopigmentation as there were no trends in transient increases over time.

ADAP adapalene 0.15%, *BPO* benzoyl peroxide 3.1%, CLIN clindamycin phosphate 1.2%, *IDP-126* clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%.




Itching
Mean Score
3
2.5
2
1.5
1
0.5
0
Severe
Moderate
Mild
Baseline
Week 2
Week 4
Week 8
Week 12
Burning
Mean Score
3
2.5
2
1.5
1
0.5
0
Severe
Moderate
Mild
Baseline
Week 2
Week 4
Week 8
Week 12
Stinging
Mean Score
3
2.5
2
1.5
1
0.5
0
Severe
Moderate
Mild
Baseline
Week 2
Week 4
Week 8
Week 12